IN THE CLAIMS:

All claim amendments and cancellations are made without prejudice or disclaimer. Please amend the claims as follows:

1. (Withdrawn – Currently amended) A process for producing a SMAD interacting protein comprising:

conducting a two-hybrid screening assay wherein SMAD C-domain fused to a DNA-binding domain is used as bait and a vertebrate cDNA library is used as prey; identifying a SMAD interacting protein in said two-hybrid assay; and

isolating said SMAD interacting protein.

2. (Currently amended) <u>An isolated SMAD</u> interacting protein produced by the process of claim 1 comprising:

conducting a two-hybrid screening assay, wherein a SMAD C-domain fused to a DNA-binding domain is used as bait and a vertebrate cDNA library is used as prey in said two-hybrid screening assay;

identifying a SMAD interacting protein in said two-hybrid assay; and isolating said SMAD interacting protein.

3. (Currently amended) A An isolated SMAD interacting protein of the family of zinc finger/homeodomain proteins including d-crystallin enhancer binding protein and/or *Drosophila* zfh-1, wherein said SMAD interacting protein:

does not interact with full size XSMAD1 in yeast,

SIP1_{ezf}-binds to E2 box sites,

SIP1_{ezf}-binds to the Brachyury protein binding site,
interferes with Brachyury-mediated transcription activation in cells, and
interacts with a C-domain of SMAD 1, 2 and/or 5.

4-7. (Canceled)

Appl. No. 09/964,238 Amdt. dated May 17, 2004 Reply to the Office Action of February 20, 2004

8. (Currently amended) A An isolated polypeptide comprising the amino acid sequence of SEQ ID NO: 2 or a functional fragment thereof, wherein said functional fragment binds to the SMAD1 C-domain in a yeast two-hybrid assay, wherein said SMAD1 C-domain is expressed as a DNA-binding domain fusion in said assay.

9. (Canceled)

10. (previously presented) A pharmaceutical composition comprising the polypeptide of claim 8, together with a suitable carrier.

11-17. (Canceled)

18. (Withdrawn) A polypeptide comprising the amino acid sequence of SEQ ID NO: 4 or a functional fragment thereof.

19-20. (Canceled)

- 21. (Currently amended) A An isolated polypeptide comprising the amino acid sequence depicted as the one letter code QHLGVGMEAPLLGFPTMNSNLSEVQKVLQIVDNTVSRQKMDCKTEDISKLK (SEQ ID NO: 21) necessary for binding with SMAD.
 - 22. (Withdrawn) A SMAD interacting protein of a family of proteins which contain a cluster of 5 CCCH-type zinc fingers including *Drosophila* "Clipper" and Zebrafish "No arches" wherein said SMAD interacting protein

interacts with full size XSMAD1 in yeast, binds single or double stranded DNA, Appl. No. 09/964,238 Amdt. dated May 17, 2004 Reply to the Office Action of February 20, 2004

has an RNase activity, and interacts with C-domain of SMAD1, 2 and/or 5.

23. (Canceled)

- 24. (New) The isolated polypeptide of claim 8, wherein the functional fragment is selected from the group consisting of amino acids 44-236 of SEQ ID NO:2, amino acids 166-236 of SEQ ID NO:2, and amino acids 44-216 of SEQ ID NO:2.
- 25. (New) An isolated polypeptide comprising the amino acid sequence of SEQ ID NO: 2 or a fragment that binds to an E2 box site in an electrophoretic mobility shift assay.
- 26. (New) The isolated polypeptide of claim 25, wherein the functional fragment comprises amino acids 977-1214 of SEQ ID NO:2.